Accelerating Molecule to Market Timelines by Maximizing Resource Utilization

The Challenge:

Pfizer is currently addressing two industry-wide disruptions: an increasing difficulty to deliver blockbuster drugs and a shift towards precision medicines for cancers and rare diseases. These shifts led to two bold initiatives by CEO Albert Bourla. The first initiative focuses on accelerated delivery of medicines to the market by reducing operational cycle times across product development. The second initiative focuses on portfolio diversification, with a goal of bringing 25 new drugs to market by 2025 and an emphasis on delivering breakthrough therapies to meet unmet patient needs globally.

View team project summary
2019 Spotlight 3rd Place Pfizer Team

Student Team

Andrés Fuentes-Afflick – Master of Business Administration

Jason Ji – EGL (BSE Chemical Engineering, MSE Industrial & Operations Engineering)


Project Sponsors

Ross MacRae – Senior Director, Drug Product Supply

Paul Stuart – VP, Drug Product Supply

Chris Turnbull – Informatics Lead, Drug Product Supply


Faculty Advisors

Brian Talbot – Ross School of Business

Henry Wang – College of Engineering


Project Photos